[Prognosis and Therapy of Myelodysplastic Syndrome].

Bonadies, Nicolas (2022). [Prognosis and Therapy of Myelodysplastic Syndrome]. Therapeutische Umschau, 78(2), pp. 93-105. Hogrefe 10.1024/0040-5930/a001334

Full text not available from this repository.

Prognosis and Therapy of Myelodysplastic Syndrome Abstract. The myelodysplastic syndromes (MDS) represent a heterogeneous group of diseases affecting the hematopoietic stem cells, which are characterized by reduced blood cells (cytopenia), maturation disorders (dysplasia) and an increased risk of transformation into acute myeloid leukemia (AML). For adequate treatment, disease and patient-related factors must be taken into account and the therapies are very different for lower- and higher-risk diseases, respectively. In the case of lower-risk diseases, the focus is on improving cytopenias and quality of life, while in the case of higher-risk diseases the prolongation of survival with a delay of transformation to AML. Only a small proportion of higher-risk MDS patients qualify for the only potentially curative treatment of hematopoietic stem cell transplantation. This review article summarizes the most important aspects of prognosis and therapy in MDS patients for the practicing physician.

Item Type:	Journal Article (Review Article)
Division/Institute:	04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Unit Childrens Hospital > Forschungsgruppe Hämatologie (Erwachsene)
UniBE Contributor:	Bonadies, Nicolas
Subjects:	600 Technology > 610 Medicine & health
ISSN:	0040-5930
Publisher:	Hogrefe
Language:	German
Submitter:	Pubmed Import
Date Deposited:	17 Mar 2022 11:56
Last Modified:	05 Dec 2022 16:15
Publisher DOI:	10.1024/0040-5930/a001334
PubMed ID:	35291847
URI:	https://boris.unibe.ch/id/eprint/167517